Huisheng Biotech: Net loss in 2024 was 2015.56 million yuan, turning from profit to loss.

According to the announcement of Hui Sheng Biotechnology, the operating income in 2024 was 1.2 billion RMB, an increase of 17.71% compared to the previous year. The net loss attributable to the shareholders of the listed company was 201.556 million RMB, compared to a net profit of 167.808 million RMB in the same period last year, turning from profit to loss. The profit distribution plan approved by the board of directors for this year is as follows: based on the total share capital of 166 million shares as of December 31, 2024, excluding 753,600 shares held in the repurchase special securities account, the total share capital is 165 million shares as the base. Cash dividends of 1.3 RMB per 10 shares will be distributed to all shareholders, with no bonus shares given, and no additional shares allocated from the capital reserve to all shareholders.